Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group

Japanese Journal of Cancer Research : Gann
K ShimizuMasakazu Nitta

Abstract

A cooperative randomized clinical trial to compare the effectiveness of multi-drug combination chemotherapy (VMCP), vincristine-melphalan-cyclophosphamide-prednisolone) with CP (cyclophosphamide-prednisolone) for the treatment of multiple myeloma was performed. When the whole group of patients was evaluated, the choice of chemotherapy (VMCP or CP) was not a significant prognostic factor associated with response or survival by uni- or multivariate analysis, and the difference between the survival curves of the treatment groups was only marginally significant. However, when the analysis was confined to stage III patients, the choice of chemotherapy became a significant prognostic factor associated with both response rate and survival, and the statistical difference between survival curves was significant. Taking the disease characteristics of multiple myeloma into consideration, the better result obtained with multi-drug combination chemotherapy in the treatment of stage III patients is consistent with other studies supporting the superiority of multi-drug combination chemotherapy for patients with overt systemic disease.

References

Oct 4, 1979·The New England Journal of Medicine·D E BergsagelA B Miller
Sep 1, 1988·Archives of Internal Medicine·R AlexanianD Dixon
Jun 1, 1988·European Journal of Cancer & Clinical Oncology·D PeestI Schedel
Aug 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B G DurieJ J Costanzi
Feb 1, 1985·Postgraduate Medical Journal·D E Bergsagel
Feb 17, 1969·JAMA : the Journal of the American Medical Association·S L Rivers, M E Patno
Aug 1, 1972·Cancer·R AlexanianH Wilson
Feb 1, 1984·Cancer·R Alexanian, R Dreicer
Aug 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E SalmonD O Dixon
Jul 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S PavlovskyA B Huberman
Jul 1, 1980·The Medical Clinics of North America·J M Paredes, B S Mitchell
Jun 12, 1980·The New England Journal of Medicine·R A Kyle, P R Greipp

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.